Special Issue

Novel Antimicrobial Strategies to Combat Biofilm Infections

Message from the Guest Editors

Bacterial biofilms are prevalent in biotic and abiotic surfaces, causing complications of bacterial eradication in tissues, medical devices, implants, and catheters. The narrow pipeline of antibiotics and the development of resistance even to last resort antibiotics raises the urgent demand for novel antibacterial interventions. This special issue targets novel antimicrobial strategies to combat biofilm infections in clinical settings, including but not limited to:

- Combination of standard of care antibiotics
- Bacteriophages and bacteriophage derived enzymes
- PK/PD models of biofilm eradication using novel antimicrobial agents *in-vitro, in-silico* and *in-vivo*
- Antimicrobial peptides
- Modified formulations such as liposomal formulations of standard of care antibiotics
- Clinical outcomes research/case reports related to novel strategies for combating biofilms
- Novel strategies against polymicrobial biofilms
- Surface modification strategies to prevent biofilm formation
- Use of biofilm inhibitors
- Repurposing non-antibiotic drugs
- Use of certain metabolite inhibitors

Guest Editors

Dr. Razieh Kebriaei

P3 Research Laboratory, College of Pharmacy, The Ohio State University, Columbus, OH, USA

Dr. Yuanpu Peter Di

Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA, USA

Deadline for manuscript submissions

closed (30 September 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed

mdpi.com/si/108330

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI